Baird lowered the firm’s price target on Contineum (CTNM) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated its model following the announcement of the unfortunate trial miss for PIPE-307 RRMS however, the core thesis for 2026 remains unchanged.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Contineum price target lowered to $22 from $25 at RBC Capital
- Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
- Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF
- Closing Bell Movers: Elastic down 12% despite beat and raise
- Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments